FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic Fibrosis
December 21st 2024The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).
Read More
Phage Therapy: Exploring the Future of Infection Treatment
Phage therapy, which uses lytic bacteriophages to target antibiotic-resistant bacteria, has resurfaced as a promising treatment for multidrug-resistant infections, but faces challenges in regulation, production, and clinical implementation despite its growing evidence of efficacy.
Read More